LEASE BY AND BETWEENIntrobiotics Phamaceuticals Inc • January 27th, 2000
EXHIBIT 99.2 LEASE TERMINATION AGREEMENT This LEASE TERMINATION AGREEMENT ("Agreement") is made and entered into as of November 22, 2002, by and between EOP-SHORELINE TECHNOLOGY PARK, L.L.C., a Delaware limited liability company ("LANDLORD"), and...Common Stock Purchase Agreement • November 27th, 2002 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
EXHIBIT 10.13 LOAN AND SECURITY AGREEMENT INTRABIOTICS PHARMACEUTICALS, INC. TABLE OF CONTENTSLoan and Security Agreement • January 27th, 2000 • Introbiotics Phamaceuticals Inc
8,500,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2012 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
RECITALSIndemnity Agreement • January 27th, 2000 • Introbiotics Phamaceuticals Inc • Delaware
EXHIBIT 10.33 LOAN MODIFICATION AGREEMENT This Loan Modification Agreement is entered into as of June 10, 2002, by and between Intrabiotics Pharmaceuticals, Inc. (the "Borrower") and Silicon Valley Bank ("Bank"). 1. DESCRIPTION OF EXISTING...Loan Modification Agreement • August 14th, 2002 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations
Common StockIntrabiotics Pharmaceuticals Inc /De • March 17th, 2000 • Pharmaceutical preparations • Maryland
ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENTCommon Stock Warrant Agreement • December 23rd, 2011 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and, a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENTWarrant Agreement • December 23rd, 2011 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENTPreferred Stock Warrant Agreement • December 23rd, 2011 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
SHORELINE TECHNOLOGY PARK MOUNTAIN VIEW, CALIFORNIA OFFICE LEASE AGREEMENTOffice Lease Agreement • February 29th, 2000 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
EXHIBIT 10.30 COMMON STOCK AND WARRANT PURCHASE AGREEMENT IntraBiotics Pharmaceuticals, Inc. 2483 East Bayshore Road, Suite 100 Palo Alto, California 94303 The undersigned (the "Investor"), hereby confirms its agreement with you as follows: 1. This...Common Stock and Warrant Purchase Agreement • October 9th, 2003 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
Exhibit 4.2 INTRABIOTICS PHARMACEUTICALS, INC. AMENDED AND RESTATED INVESTORS RIGHTS AGREEMENT OCTOBER 15, 1999 TABLE OF CONTENTS -----------------Rights Agreement • January 27th, 2000 • Introbiotics Phamaceuticals Inc • California
RECITALSLease Termination Agreement • March 31st, 2003 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations
EXHIBIT 10.19 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR...Introbiotics Phamaceuticals Inc • January 27th, 2000 • California
EXHIBIT 10.5 DEVELOPMENT SUPPLY AGREEMENTCertain • March 23rd, 2000 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
ARDEA BIOSCIENCES, INC. AND [TRUSTEE], TRUSTEE FORM OF SUBORDINATED DEBT INDENTUREArdea Biosciences, Inc./De • December 23rd, 2011 • Pharmaceutical preparations • New York
INDENTURE, dated as of , 20 , among ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
EXHIBIT 4.4 AMENDMENT TO THE PREFERRED STOCK AND WARRANT PURCHASE AGREEMENT This Amendment (the "AMENDMENT") to that certain Preferred Stock and Warrant Purchase Agreement (the "AGREEMENT") dated as of February 5, 2003 and amended as of February 11,...Preferred Stock and Warrant Purchase Agreement • May 14th, 2003 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations
EQUIPMENT FINANCING AGREEMENT (Number 10782)Equipment Financing Agreement • January 27th, 2000 • Introbiotics Phamaceuticals Inc • California
RECITALSAnd Assumption Agreement • March 31st, 2003 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 15th, 2002 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
Please confirm that the foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.
OFFICE LEASE EMBARCADERO CORPORATE CENTEROffice Lease • March 31st, 2003 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
EXHIBIT I Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required on Schedule 13G need be filed with respect to ownership by each of the...Intrabiotics Pharmaceuticals Inc /De • July 3rd, 2002 • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required on Schedule 13G need be filed with respect to ownership by each of the undersigned of shares of Common Stock of Intrabiotics Pharmaceuticals, Inc.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND IS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. EXHIBIT 10.8 LICENSE...License and Supply Agreement • March 23rd, 2000 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • New York
3,000,000 Shares Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • April 22nd, 2004 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • New York
IntraBiotics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representatives (the “Representatives”) an aggregate of 3,000,000 shares of the Company’s Common Stock, $0.001 par value per share (the “Firm Shares”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 450,000 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below.
SECOND AMENDMENT TO LICENSE AGREEMENT M940121 (UNMARKED)Certain • March 23rd, 2000 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • California
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 18th, 2008 • Ardea Biosciences, Inc./De • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 17, 2008, by and among Ardea Biosciences, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
June 1, 2001 John Fiddes [address]Letter Agreement • August 14th, 2001 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations
This Letter Agreement (the “Letter Agreement”) is to inform you in advance that IntraBiotics Pharmaceuticals, Inc. (the “Company”) is restructuring its workforce at its facilities located at 2021 Stierlin Court, Mountain View, California and 1245 Terra Bella, Mountain View, California. This restructuring constitutes a “mass layoff” under the WARN Act.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 22nd, 2008 • Ardea Biosciences, Inc./De • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 17, 2008, by and among Ardea Biosciences, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
RESEARCH AND TECHNOLOGY AGREEMENTResearch and Technology Agreement • May 11th, 2001 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations • Delaware
This Research and Technology Agreement (the “Agreement”) is made effective as of January 24, 2001 (the “Effective Date”) between INTRABIOTICS PHARMACEUTICALS, INC., a Delaware corporation, having its principal place of business in Mountain View, California (hereinafter referred to as “INTRABIOTICS”), and NEW CHEMICAL ENTITIES, INC., a Delaware corporation having a principal place of business in Bothell, Washington (hereinafter referred to as “NCE”).
SUBLEASESublease • March 24th, 2008 • Ardea Biosciences, Inc./De • Pharmaceutical preparations
This SUBLEASE (“Sublease”), dated October___, 2007 for reference purposes only, is entered into by and between VERENIUM CORPORATION, a Delaware corporation (“Sublandlord”), and ARDEA BIOSCIENCES, INC., a Delaware corporation (“Subtenant”).
June 21, 2001Intrabiotics Pharmaceuticals Inc /De • August 14th, 2001 • Pharmaceutical preparations
This letter (“Letter”) will serve to confirm the mutual release and termination of the Agreement between IntraBiotics and AMRI as reflected in your email of June 11, 2001. Capitalized terms contained in this Letter shall have the meaning set forth in the Agreement.
April 23, 2002 To the Stockholders of Apothogen, Inc. Listed on the Signature Page hereto Re: IntraBiotics Pharmaceuticals, Inc. — Registration Rights Gentlemen:Merger Agreement • May 15th, 2002 • Intrabiotics Pharmaceuticals Inc /De • Pharmaceutical preparations
In connection with the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) among IntraBiotics Pharmaceuticals, Inc., a Delaware corporation (“IntraBiotics”), APN Acquisition Corp., Apothogen, Inc., a Delaware corporation, and the stockholders of Apothogen (the “Stockholders”) entered into on even date herewith, as an additional inducement for the Stockholders to enter into the Merger Agreement, IntraBiotics hereby agrees to grant to the Stockholders certain registration rights relating to the shares of Common Stock to be issued by IntraBiotics to the Stockholders pursuant to the Merger Agreement (the “Shares”). Capitalized terms used herein but not defined shall have the meanings ascribed to them in the Merger Agreement.
VOTING AGREEMENTVoting Agreement • April 24th, 2012 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • Delaware
This VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc. (“Parent”) and the undersigned stockholder (the “Stockholder”) of Ardea BioSciences, Inc., a Delaware corporation (the “Company”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 22nd, 2008 • Ardea Biosciences, Inc./De • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of December 17, 2008, by and among Ardea Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
